← All trials
NCT06470256
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2024
- Primary completion
- Jun 1, 2027
- Completion date
- Jun 1, 2028
- First posted
- Jun 24, 2024
- Last posted
- Jun 24, 2024
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyOfficial
- Wuhan Central HospitalCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Xiamen UniversityCollaborator
- Wuhan UniversityCollaborator
- Wuhan UniversityCollaborator
- Shiyan Taihe HospitalCollaborator
- Central South UniversityCollaborator
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.